Adicet Bio (ACET) vs Aldeyra Therapeutics (ALDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adicet Bio (ACET) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 61.4% versus a loss of 82.9%. Over five years, ALDX leads with a -88.5% price change compared with -95.5% for ACET. Aldeyra Therapeutics is the larger company by market cap ($57.2 million vs $53.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | ALDX |
|---|---|---|
| Share price | $5.74 | $0.9477 |
| Market cap | $53.73M | $57.17M |
| 1-day change | -7.12% | -1.14% |
| YTD return | -31.83% | -81.49% |
| 1-year return | -61.38% | -82.91% |
| 5-year return | -95.54% | -88.51% |
| EPS (TTM) | $-9.61 | $-0.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.44 | $5.93 |
| 52-week low | $5.55 | $0.862 |
| Distance from 52-week high | -67.09% | -84.02% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +506.79% | +596.42% |
| Average volume | 172.38K | 1.18M |
| Shares outstanding | 9.36M | 60.33M |
| Employees | 102 | 6 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACET has outperformed ALDX by 21.5 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Healthcare · Biotechnology · 102 employees
About Aldeyra Therapeutics
ALDX stock →Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Healthcare · Biotechnology · 6 employees
ACET vs ALDX FAQ
Which is bigger, Adicet Bio or Aldeyra Therapeutics?
Aldeyra Therapeutics (ALDX) is larger, with a market capitalization of $57.17M compared with $53.73M for Adicet Bio (ACET).
Which stock has performed better over the past year, ACET or ALDX?
ACET returned -61.38% over the past 12 months, compared with -82.91% for ALDX (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and Aldeyra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.